Wegovy vs. Saxenda

See how Wegovy and Saxenda compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Wegovy is injected once a week while Saxenda requires a daily injection, a major convenience difference for many patients.

  • Wegovy is the only one of the two FDA-approved to reduce cardiovascular risk in adults with established heart disease and obesity or overweight.

  • Both drugs share the same boxed warning for thyroid C-cell tumors and cause similar GI side effects, though the exact rates differ slightly between them.

Wegovy vs. Saxenda Drug Summary

Wegovy

Wegovy (semaglutide) is a GLP-1 receptor agonist used for chronic weight management in adults and adolescents with obesity, and to reduce cardiovascular risk in adults with heart disease and obesity. It is injected once a week, with the dose gradually increased over about four months to a 2.4 mg maintenance level.

Saxenda

Saxenda (liraglutide) is a GLP-1 receptor agonist used for chronic weight management in adults and adolescents with obesity. It is injected once a day, with the dose increased weekly over about a month until it reaches the 3 mg maintenance level.

Wegovy vs. Saxenda Side Effects

Wegovy

Most common
nausea (up to 44%)
diarrhea (up to 30%)
constipation (up to 24%)
vomiting (up to 24%)

Saxenda

Most common
nausea (up to 39.3%)
diarrhea (up to 20.9%)
constipation (up to 19.4%)
vomiting (up to 15.7%)

Wegovy vs. Saxenda Dosage

Wegovy

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 0.25 mg once weekly Weeks 1-4
Maximum dose 2.4 mg once weekly Week 17 onward
Dose changes 4 increases Every 4 weeks

Saxenda

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 0.6 mg once daily Week 1
Maximum dose 3 mg once daily Week 5 onward
Dose changes 4 increases Every week

Wegovy vs. Saxenda Indications

Wegovy

Wegovy is FDA-approved for chronic weight management in adults and adolescents 12 and older who have obesity, or overweight with a weight-related condition, alongside diet and exercise. It is also approved to lower the risk of major cardiovascular events in adults with established heart disease who have obesity or overweight.

  • Weight management in adults with obesity or overweight plus a weight-related condition

  • Weight management in adolescents 12 and older with obesity

  • Reduce cardiovascular risk in adults with obesity or overweight and heart disease

Saxenda

Saxenda is FDA-approved for chronic weight management in adults who have obesity, or overweight with a weight-related condition, alongside diet and exercise. It is also approved for adolescents ages 12 to 17 with obesity.

  • Weight management in adults with obesity or overweight plus a weight-related condition

  • Weight management in adolescents 12 to 17 with obesity

  • Used together with diet and exercise

Wegovy vs. Saxenda Pros and Cons

Wegovy

Wegovy's once-weekly schedule and its added cardiovascular indication set it apart from Saxenda, though the two drugs share the same class-wide warnings. Insurance coverage for either drug varies widely and often depends on the specific diagnosis code used for approval.

Pros

  • Only needs one injection per week instead of daily

  • FDA-approved to reduce risk of heart attack, stroke, and cardiovascular death in adults with heart disease

  • Uses a higher maintenance dose (2.4 mg) that may support greater weight loss

Cons

  • Newer drug with less long-term real-world experience than Saxenda

  • Reported rates of nausea and vomiting are somewhat higher than Saxenda's

  • Same thyroid tumor boxed warning, so the same contraindications apply

Saxenda

Saxenda has a longer track record since its 2014 approval, but its daily injection requirement is a meaningful trade-off against Wegovy's weekly dosing. Both drugs carry the same thyroid tumor boxed warning and depend on insurance formularies for affordability.

Pros

  • Approved since 2014, giving it a longer track record in clinical use

  • Slightly lower reported rates of nausea and vomiting in trials

  • Daily dosing allows finer day-to-day adjustment of injection timing

Cons

  • Requires a daily injection instead of once a week

  • Label carries added warnings for increased heart rate and suicidal thoughts monitoring

  • Not approved for cardiovascular risk reduction like Wegovy

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.